HBM Healthcare Investments focuses on generating long-term capital gains by investing in private and public companies across the human medicine, biotechnology, medical technology, and diagnostics sectors. Their strategy emphasizes predominantly later-stage private companies with strong business models and attractive valuations, alongside investments in public companies, many of which were initially private equity holdings.
70% of their portfolio is in Biotech & Life Sciences. They made 1 investments in the last 12 months. Their most common stage is series-c (50% of deals). Average disclosed round size is $157.4M (across 10 rounds with reported amounts).
Portfolio
10
Fund Size
$1.9B
Top Stage
Series C
Last 12 Mo
1
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
10 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Electra Therapeutics | Series C | $183M | Oct 2025 |
 Alumis Inc | Series C | $259M | Mar 2024 |
 Odyssey Therapeutics, Inc. | Series B | $168M | Oct 2022 |
| Odyssey Therapeutics, Inc. | Series A | $218M | Dec 2021 |
 Freenome | Series D | $300M | Dec 2021 |
 Neurelis, Inc. | Series D | $114M | Mar 2021 |
 NiKang Therapeutics | Series B | $50M | Sep 2020 |
 Seer, Inc. | Series C | $55M | Jul 2020 |
 Karius | Series C | $165M | Feb 2020 |
 Complexa Inc. | Series C | $62M | Jul 2017 |
Top Co-Investors
Cormorant Asset Management4 shared
OrbiMed3 shared
SR One3 shared
Foresite Capital3 shared
Logos Capital3 shared
Woodline Partners2 shared
Colt Ventures2 shared
General Catalyst2 shared
T. Rowe Price Associates, Inc.2 shared
Catalio Capital Management2 shared
Lilly Asia Ventures2 shared
RA Capital Management2 shared
SoftBank Vision Fund1 shared
Khosla Ventures1 shared
Lightspeed Venture Partners1 shared
Walleye Capital1 shared
Alexandria Venture Investments1 shared
JAFCO1 shared
Matrix Partners1 shared
Last updated: 8 March 2026